<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="183523">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705133</url>
  </required_header>
  <id_info>
    <org_study_id>07-11-087-01</org_study_id>
    <nct_id>NCT00705133</nct_id>
  </id_info>
  <brief_title>Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension</brief_title>
  <official_title>Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance,
      hemodynamics and quality of life in patients with interstitial lung disease and severe
      secondary pulmonary arterial hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">February 2009</completion_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic parameters</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and shortness of breath indices</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Interstitial Lung Disease</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with idiopathic pulmonary fibrosis with severe pulmonary arterial hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treprostinil</intervention_name>
    <description>For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min per day initially as tolerated and then increased by 0.5ng/kg/min every 2 days as an outpatient. The maximum dose at 3 months will be 40ng/kg/min</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible subjects must have IPF and severe PAH documented on standard of care right-heart
        catheterization (RHC) and planned to receive therapy with treprostinil as recommended by
        the treating physician.

          1. All subjects must have high resolution CT scan (HRCT) diagnostic of IPF (performed as
             part of standard of care evaluation) or if available, biopsy proven histological
             usual interstitial pneumonia (UIP).

          2. Severe pulmonary arterial hypertension defined as a resting mean pulmonary artery
             pressure (mPAP) &gt; 35 mm Hg; AND pulmonary vascular resistance (PVR) &gt; 3 woods-units;
             AND pulmonary capillary wedge pressure (PCWP) &lt; 18 mm Hg by right-heart
             catheterization (RHC) performed as part of standard of care evaluation.

          3. All subjects must be planned to receive treprostinil therapy as recommended by their
             treating physician.

        Exclusion Criteria:

          1. Acute or chronic impairment other than dyspnea (e.g. angina pectoris, intermittent
             claudication) limiting the ability to perform standard of care six-minute walk tests
             (6MWT).

          2. Six-minute walk distance (6MWD) &lt; 50 meters at screening or baseline standard of care
             evaluations

          3. Standard of care pulmonary function test (PFT) showing forced expiratory volume in
             one second (FEV1)/ forced vital capacity (FVC) ratio &lt; 0.65

          4. Standard of care pulmonary function test (PFT) showing a residual volume &gt;120%
             predicted

          5. Standard of care high-resolution chest computed tomography (HRCT) showing emphysema
             extent &gt; 30%

          6. Any investigational therapy as part of a clinical trial for any indication with 30
             days before screening

          7. Change in dose of treatment for IPF - investigational agent (gamma interferon-1b,
             pirfenidone, etanercept, and any other investigational agent intended to treat IPF),
             corticosteroids, or cytotoxic agents, within 30 days before screening. That is,
             subjects can be on any of these agents provided the dose is stable for at least 30
             days prior to enrollment.

          8. Current treatment for pulmonary hypertension with other prostaglandins (epoprostenol
             or iloprost)

          9. Change in dose of treatment for PAH - (bosentan, sitaxsentan, ambrisentan, tadalafil,
             sildenafil, vardenafil, calcium channel blockers, nitrates, digitalis), within 30
             days before screening. That is, subjects can be on any of these agents provided the
             dose is stable for at least 30 days prior to enrollment

         10. Pulmonary rehabilitation initiated within 30 days of baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajan Saggar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>David Geffen School of Medicine, UCLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Zisman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>David Geffen School of Medicine, UCLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajan Saggar, MD</last_name>
    <phone>310-825-5635</phone>
    <email>rsaggar@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Lopez, RN</last_name>
    <email>plopez@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>David Geffen School of Medicine, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Lopez, RN</last_name>
      <email>plopez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Rajan Saggar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Zisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajeev Saggar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shelley Shapiro, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <lastchanged_date>June 24, 2008</lastchanged_date>
  <firstreceived_date>June 23, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Rajan Saggar MD</name_title>
    <organization>David Geffen School of Medicine, University of California, Los Angeles</organization>
  </responsible_party>
  <keyword>pulmonary hypertension</keyword>
  <keyword>pulmonary fibrosis</keyword>
  <keyword>interstitial lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
